Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2431 to 2445 of 9060 results

  1. Donanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID6222]

    In development Reference number: GID-TA11221 Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Cabozantinib for treating advanced neuroendocrine tumours that have progressed after systemic treatment [ID6474]

    In development Reference number: GID-TA11613 Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Bladder cancer: diagnosis and management (update)

    In development Reference number: GID-NG10452 Expected publication date: TBC

    NICE guideline
    In development

  4. In-situ normothermic regional perfusion of the abdomen for livers donated after controlled circulatory death

    In development Reference number: GID-HTG10880 Expected publication date:  19 November 2026

    HealthTech guidance
    In development

  5. Extravascular implantable cardioverter defibrillator insertion for preventing sudden cardiac death caused by ventricular arrhythmia

    In development Reference number: GID-HTG10882 Expected publication date:  08 April 2027

    HealthTech guidance
    In development

  6. Blood-based biomarker tests for surveillance in people at risk of hepatocellular carcinoma

    In development Reference number: GID-HTG10175 Expected publication date: TBC

    HealthTech guidance
    In development

  7. Monofocal intraocular lenses for cataract surgery

    In development Reference number: GID-HTG10875 Expected publication date:  10 March 2027

    HealthTech guidance
    In development

  8. Suspected sepsis: recognition, diagnosis and early management - procalcitonin testing

    In development Reference number: GID-NG10467 Expected publication date:  11 September 2026

    NICE guideline
    In development

  9. Inavolisib with pertuzumab–trastuzumab for maintenance treatment of PIK3CA-mutated HER2-positive advanced breast cancer after induction chemotherapy

    Awaiting development Reference number: GID-TA12441 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Zilovertamab vedotin in combination for treating relapsed or refractory diffuse large B-cell lymphoma

    Awaiting development Reference number: GID-TA12458 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Xanomeline tartrate–trospium chloride for treating psychosis associated with Alzheimer's disease

    Awaiting development Reference number: GID-TA12460 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Imlunestrant for adjuvant treatment of ER-positive, HER2-negative early breast cancer with increased risk of recurrence

    Awaiting development Reference number: GID-TA12459 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. CaRi-Heart for predicting cardiac risk in adults with suspected coronary artery disease (CAD)

    In development Reference number: GID-HTG10885 Expected publication date:  02 December 2026

    HealthTech guidance
    In development

  14. Allo-APZ2-CVU for treating chronic venous leg ulcers [ID6754]

    Awaiting development Reference number: GID-TA11988 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Durvalumab with radiotherapy for treating unresected node-negative stage 1 or 2 non-small-cell lung cancer [ID6567]

    Awaiting development Reference number: GID-TA11747 Expected publication date:  14 April 2027

    Technology appraisal guidance
    Awaiting development